Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Eisai Building Second Production Facility in Suzhou

publication date: Apr 25, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Eisai, the Japanese biopharma, announced plans to build a new production facility in Suzhou, alongside its current China plant. The new facility will make injectible drugs, especially Methycobal®, a treatment for peripheral neuropathies and one of Eisai’s major products in China. According to Eisai, its China sales are growing, a trend it expects to continue, and the company wants to insure a steady supply of products. More details....

Stock Symbol: (TO: 4523)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...